Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886568 | 0.98 | FFAR1 (0.51) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL29187197 | 0.98 | FFAR1 (0.51) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL21623413 | 0.90 | HDAC8 (0.42) | FFAR1FFAR4MMP2MMP12CYP3A4 | |
| SCHEMBL21623404 | 0.88 | DRD2 (0.41) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL21623412 | 0.86 | HDAC8 (0.42) | FFAR1CYP3A4CYP2D6CHRNB2CHRNA4 | |
| SCHEMBL5886652 | 0.84 | FFAR1 (0.63) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL1838704 | 0.81 | KDM4E (0.46) | FFAR1FFAR4CYP3A4CHRNB2CHRNA4 | |
| SCHEMBL5314931 | 0.80 | FFAR1 (0.55) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5886588 | 0.79 | FFAR1 (0.53) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL3064618 | 0.79 | CHRNB2 (0.67) | MMP2MMP12KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688634-B2 | Pest control agent | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-9688634-B2 | Pest control agent | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| CN-105142401-A | Pest control agent | ISHIHARA SANGYO KAISHA | 2015-12-09 | — | — | CN | disclosed |
| US-20150336894-A1 | PEST CONTROL AGENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2015-11-26 | — | — | US | disclosed |
| US-20150336894-A1 | PEST CONTROL AGENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2934137-A1 | PEST CONTROL AGENT | Ishihara Sangyo Kaisha, Ltd. (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934137-A1 | PEST CONTROL AGENT | Ishihara Sangyo Kaisha, Ltd. (JP) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014098259-A1 | PEST CONTROL AGENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014098259-A1 | PEST CONTROL AGENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2014-06-26 | — | — | WO | disclosed |
| EP-0886754-B1 | NON-COMPETITIVE IMMUNOASSAY WITH BLOCKING OF UNOCCUPIED SPECIFIC BINDING SITES ON SOLID PHASE | WALLAC OY (FI) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336894-A1 | PEST CONTROL AGENT | DDT, CTRL, PTP4A1 | FFAR1 4608/4885FFAR4 3671/4885MMP2 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.